Search - tctmd.com

Displaying 1 - 20 of 27

Sort: Relevancy | Date

News Daily News

Year in Review: Top Prevention Stories of 2025

Michael O'Riordan

December 24, 2025

News Daily News

Inclisiran Plus Usual Care Improves LDL Control in ACS: VICTORION-INCEPTION

Michael O'Riordan

June 04, 2025

News Daily News

Inclisiran Effective as Monotherapy for Lower-Risk Primary Prevention

Michael O'Riordan

May 07, 2025

News Daily News

Lp(a) Genetics Differ Between Populations but Have Similar Clinical Impact

Yael L. Maxwell

May 05, 2025

News Daily News

Lorundrostat Lowers BP in Treatment-Resistant Hypertension: Advance-HTN

Yael L. Maxwell

April 29, 2025

News Daily News

Vutrisiran, With the FDA’s Sign-off, Joins the Fray for ATTR-CM

Caitlin E. Cox

March 21, 2025

News Daily News

Olpasiran Cuts Lp(a) but Not Inflammatory Markers: OCEAN(a)-DOSE

Yael L. Maxwell

February 14, 2025

News Daily News

Top General Cardiology and Prevention News of 2024

Caitlin E. Cox

December 30, 2024

News Daily News

Lp(a) Still Low Almost 1 Year After Last Olpasiran Injection: OCEAN(a)-DOSE

Yael L. Maxwell

August 19, 2024

News Daily News

Vutrisiran, an siRNA for ATTR-CM, Meets Primary Endpoint in HELIOS-B

Michael O'Riordan

June 24, 2024

News Daily News

Lp(a) Linked to Higher ASCVD Risks in Diverse Patient Groups

Michael O'Riordan

April 17, 2024

News Daily News

Less Is More: Lp(a) Much More Atherogenic Than LDL

Michael O'Riordan

January 16, 2024

News Daily News

PAD, AAA: High Lp(a) Portends Problems Beyond CVD

Caitlin E. Cox

December 06, 2023

News Daily News

No Safety Concerns Seen With Inclisiran in Large ORION Analysis

Michael O'Riordan

December 06, 2023

News Daily News

Evinacumab Helps Severe Hypercholesterolemia Patients Reach LDL Targets

Michael O'Riordan

September 14, 2023

News Daily News

Sustained LDL-Cholesterol Reductions With Inclisiran: ORION-3

Michael O'Riordan

January 16, 2023

News Daily News

Top General Cardiology and Prevention News of 2022

Michael O'Riordan

December 26, 2022

News Daily News

Lp(a) Levels Linked to Aortic Valve Calcification, Not Progression

Michael O'Riordan

August 08, 2022

News Daily News

FDA Approves Inclisiran, a Twice-Yearly Injection to Lower LDL Levels

Michael O'Riordan

December 22, 2021

News Daily News

British Medical Groups Express Concern About Inclisiran Rollout

Michael O'Riordan

December 14, 2021

Advertisement

Year in Review: Top Prevention Stories of 2025

Inclisiran Plus Usual Care Improves LDL Control in ACS: VICTORION-INCEPTION

Inclisiran Effective as Monotherapy for Lower-Risk Primary Prevention

Lp(a) Genetics Differ Between Populations but Have Similar Clinical Impact

Lorundrostat Lowers BP in Treatment-Resistant Hypertension: Advance-HTN

Vutrisiran, With the FDA’s Sign-off, Joins the Fray for ATTR-CM

Olpasiran Cuts Lp(a) but Not Inflammatory Markers: OCEAN(a)-DOSE

Top General Cardiology and Prevention News of 2024

Lp(a) Still Low Almost 1 Year After Last Olpasiran Injection: OCEAN(a)-DOSE

Vutrisiran, an siRNA for ATTR-CM, Meets Primary Endpoint in HELIOS-B

Lp(a) Linked to Higher ASCVD Risks in Diverse Patient Groups

Less Is More: Lp(a) Much More Atherogenic Than LDL

PAD, AAA: High Lp(a) Portends Problems Beyond CVD

No Safety Concerns Seen With Inclisiran in Large ORION Analysis

Evinacumab Helps Severe Hypercholesterolemia Patients Reach LDL Targets

Sustained LDL-Cholesterol Reductions With Inclisiran: ORION-3

Top General Cardiology and Prevention News of 2022

Lp(a) Levels Linked to Aortic Valve Calcification, Not Progression

FDA Approves Inclisiran, a Twice-Yearly Injection to Lower LDL Levels

British Medical Groups Express Concern About Inclisiran Rollout

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content